Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +46.86%
#2 Pons Pons +33.93%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +30.17%
#4 Starpower Starpower +28.77%
#5 SkyAI SkyAI +23.54%
#6 TENDIES TENDIES +23.41%
#7 Mubarak Mubarak +22.85%
#8 StonkBroker StonkBroker +21.88%
#9 Ocean Protocol Ocean Protocol +21.10%
#10 PondCoin PondCoin +20.54%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Settings
Language
ENGLISH
Currency
USD
Theme
ABVC BioPharma, Inc. ABVC BioPharma, Inc.

ABVC BioPharma, Inc.

ABVC
Rank in Stocks #28788
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on... ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer. ABV-1504 has successfully completed Phase II clinical trials for major depressive disorders. ABV-1505 is progressing through Phase II clinical studies for attention deficit hyperactivity disorder (ADHD). ABV-1703 has concluded its Phase I clinical trials for the treatment of pancreatic cancer. ABV-1702 has also finished Phase I clinical investigations for myelodysplastic syndromes. ABV-1601 is in Phase I/II clinical trials, aimed at alleviating depression in individuals with cancer. ABV-1701 Vitargus is in development to treat conditions such as retinal detachment or vitreous hemorrhage. ABVC BioPharma maintains strategic alliances, including a co-development arrangement with Rgene Corporation, alongside collaborative agreements with BioHopeKing Corporation and BioFirst Corporation. The company's headquarters are located in Fremont, California, and it operates as a subsidiary of YuanGene Corporation.
Share Price
$0.9403
Market Cap
$24.45M
Change (1 day)
8.57%
Change (1 year)
-67.01%
Country
US
Trade ABVC BioPharma, Inc. (ABVC)

Category

Healthcare
P/E ratio for ABVC BioPharma, Inc. (ABVC)
P/E ratio as of 2026 TTM: 0
According to ABVC BioPharma, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for ABVC BioPharma, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.